 Shares of Heron Therapeutics Inc NASDAQ: HRTX are higher after a long wait to get regulatory approval for its non-opioid pain drug. What Happened: San Diego, California-based Heron, a commercial-stage biotechnology company focused on developing treatments for unmet patient needs, said Thursday the FDA has given its nod for its Zynrelef, codenamed previously as HTX-011, for use in adults as an extended-release dual-acting local anesthetic. 